kabutan

MediciNova,Inc.(4875) Summary

4875
TSE Standard
MediciNova,Inc.
237
JPY
-3
(-1.25%)
Dec 12, 3:30 pm JST
1.52
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
238 JPY 1.53 USD
Previous Close Dec 11
240 JPY 1.53 USD
High Dec 12, 9:50 am
240 JPY 1.54 USD
Low Dec 12, 9:39 am
235 JPY 1.50 USD
Volume
47,100
Trading Value
0.01B JPY 0.07M USD
VWAP
236.81 JPY 1.52 USD
Minimum Trading Value
23,700 JPY 152 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
115
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Mid
1-Year Average
194
1-Year High Nov 5, 2025
3,850
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 54,900
Nov 28, 2025 0 50,200
Nov 21, 2025 0 51,700
Nov 14, 2025 0 67,600
Nov 7, 2025 0 60,100
Company Profile
MediciNova, Inc. is a US-based pharmaceutical development venture focusing on treatments for conditions such as acute asthma attacks.
Sector
Pharmaceuticals
MediciNova, Inc. is a pharmaceutical development company headquartered in the United States, specializing in the development of novel therapeutics for serious diseases. Its lead development product, MN-166 (ibudilast), is being developed for indications including ALS, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence, alcohol use disorder, and Long-COVID. MN-001 (tipelukast) is being developed for non-alcoholic fatty liver disease and idiopathic pulmonary fibrosis. Additionally, a treatment for phenylketonuria is included in the development pipeline. The company has received Fast Track and Orphan Drug designations from the US FDA for several of its development products, indicating a promising development pipeline.